Department of Pathology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
© 2015 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Present case | PEL | HHV8-negative EBL | DLBCL associated with chronic inflammation | |
---|---|---|---|---|
Age at diagnosis | 39 yr | Young or middle-aged | Old (median, 70 yr) | Old (median, 65–70 yr) |
Underlying condition | Pneumocystis jirovecii pneumonia | ND | Fluid overload | Pyothorax or chronic pleuritis |
Site of involvement | Pneumonic bullae | Body cavities | Body cavities | Body cavities |
Immunophenotype | CD20(+), CD79a(+), MUM1(+), CD138(-), CD30(–) | CD20(–), CD79a(–), CD138(+), CD30(+/–) | CD20(+), CD79a(+), CD138(+/–), CD30(+/–) | CD20(+/–), CD79a(+/–), MUM1(+), CD138(+), CD30(+/–) |
Viral infection | HIV(+), HHV8(–) | HIV(+), HHV8(+) | HIV(–), HHV8(–) | HIV(–), HHV8(–) |
EBV(+, latency III), HCV(–) | EBV(+, latency II), HCV(–) | EBV(–), HCV(+, 26.5%) | EBV(+, latency III), HCV(–) | |
Prognosis | Unknown | Unfavorable (median survival, < 6 mo) | Variable (median survival, 10 mo) | Unfavorable (5-yr survival, 20%–35%) |
PEL, primary effusion lymphoma; HHV8, human herpesvirus 8; EBL, effusion-based lymphoma; DLBCL, diffuse large B-cell lymphoma; ND, not described; HIV, human immunodeficiency virus; EBV, Epstein-Barr virus; HCV, hepatitis C virus.